@article{RN10032,

title = {Impairment in cognitive function in patients with axial spondyloarthritis and psoriatic arthritis},

author = { S. Kleinert and F. Schuch and P. Rapp and M. Ronneberger and J. Wendler and P. Sternad and F. Popp and P. Bartz-Bazzanella and C. von der Decken and K. Karberg and G. Gauler and P. Wurth and S. Spathling-Mestekemper and C. Kuhn and M. Englbrecht and W. Vorbruggen and G. Adler and M. Welcker},

url = {https://www.ncbi.nlm.nih.gov/pubmed/36441274},

doi = {10.1007/s00296-022-05248-4},

issn = {1437-160X (Electronic) 

0172-8172 (Linking)},

year  = {2023},

date = {2023-01-01},

journal = {Rheumatol Int},

volume = {43},

number = {1},

pages = {89-97},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Kiltz2022-nt,

title = {Entwicklung von Qualitätsstandards für die Versorgung  von Patient*innen mit rheumatoider Arthritis zur Anwendung in  Deutschland},

author = { U Kiltz and V Buschhorn-Milberger and K Albrecht and H-J Lakomek and H-M Lorenz and M Rudwaleit and M Schneider and H Schulze-Koops and M Aringer and M I Hasenbring and P Herzer and U von Hinüber and K Krüger and A Lauterbach and B Manger and R Oltman and F Schuch and R Schmale-Grede and S Späthling-Mestekemper and S Zinke and J Braun},

url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646547/},

year  = {2022},

date = {2022-11-01},

urldate = {2022-11-01},

journal = {Z. Rheumatol.},

volume = {81},

number = {9},

pages = {744--759},

publisher = {Springer Science and Business Media LLC},

abstract = {ZusammenfassungTrotz einer qualitativ und strukturell guten 

 Versorgung von Patient*innen mit rheumatoider Arthritis (RA) in 

 Deutschland bestehen weiterhin potenziell behebbare Defizite in 

 der Qualität der Versorgung. Aus diesem Grund hat die 

 Deutsche Gesellschaft für Rheumatologie (DGRh) eine 

 Expert*innengruppe, in der verschiedene Interessengruppen 

 vertreten waren, beauftragt, nationale Qualitätsstandards 

 (QS) mit dem Ziel zu entwickeln, die rheumatologische Versorgung 

 von Patient*innen mit RA in Deutschland qualitativ zu 

 verbessern. QS dienen der Festlegung und quantitativen Messung 

 guter Versorgungsqualität unter dem Vorbehalt von Relevanz 

 und Realisierbarkeit. Als Grundlage für die Entwicklung 

 dienten die kürzlich publizierten Standards von NICE und 

 ASAS und eine systematische Literatursuche. Insgesamt wurden 8 

 hiermit erstmals veröffentlichte QS konsentiert, die als 

 Grundlage dienen können, die Versorgungsqualität von 

 Patient*innen mit RA in Deutschland zu messen und weiter zu 

 optimieren.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Pfeil2022-yp,

title = {Rheumatology training positions in Germany},

author = { Alexander Pfeil and Martin Krusche and Fabian Proft and Diana Vossen and Jürgen Braun and Xenofon Baraliakos and Michael N Berliner and Gernot Keyßer and Andreas Krause and Hanns-Martin Lorenz and Bernhard Manger and Florian Schuch and Christof Specker and Jürgen Wollenhaupt and Anna Voormann and Martin Fleck},

year  = {2022},

date = {2022-10-01},

journal = {Z. Rheumatol.},

abstract = {BACKGROUND: In the next few years many general practitioners and 

 specialists will retire. As in other disciplines the question 

 arises in rheumatology whether sufficient training positions are 

 available to maintain or expand the supply of care according to 

 demand. Therefore, the German Society of Rheumatology (DGRh) has 

 assigned its committee for education and training to review the 

 currently available training opportunities in Germany. The aim of 

 this work is the quantitative survey of the training capacity to 

 become a specialist in internal medicine and rheumatology. 

 METHODS: Within the framework of this study, a survey was 

 conducted via the homepages of the 17 state medical associations 

 to determine the postgraduate medical officers, their place of 

 work and the duration of their postgraduate training 

 capabilities. Based on the data, a nationwide survey of training 

 positions was conducted. RESULTS: Specialized rheumatology 

 training is established at 229 training centers in Germany, 

 whereby data from 187 training sites were available for analysis. 

 The training locations are distributed as followed: 52.4% 

 clinical sector and 47.6% outpatient sector. In total, 478.4 

 training positions are available in Germany (clinical sector: 

 391.4 and outpatient sector: 87) and 17.2% of the positions 

 (clinical sector: 11.4% and outpatient sector: 43.1%) are not 

 occupied. CONCLUSION: Based on this study, it can be shown that 

 most of the continuing education positions are available in the 

 clinical sector. In contrast, half of the training positions in 

 the outpatient area are not filled. In order to improve the 

 training situation, it is essential to integrate outpatient 

 colleagues into the training program. This presupposes that 

 further training is supported or financed by the healthcare 

 system. In this context, optimal rheumatological care must be 

 permanently guaranteed throughout Germany in order to provide 

 sufficient care for the approximately 2 million patients with 

 inflammatory rheumatic diseases.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Horbrand2022-jn,

title = {PHARAO-Studie: Arzneimittelversorgung entzündlich 

 rheumatischer Erkrankungen},

author = { Franziska Hörbrand and Florian Schuch and Hans-Holger Bleß and David Messinger and Bork Bretthauer and Peter Killian},

year  = {2022},

date = {2022-08-01},

journal = {Z. Rheumatol.},

publisher = {Springer Science and Business Media LLC},

abstract = {Zusammenfassung Hintergrund Mit Einführung der 

 Tumornekrosefaktor(TNF)-$alpha$-Blocker hat die Behandlung 

 entzündlich rheumatischer Erkrankungen (ERE) einen 

 grundlegenden Wandel erfahren. Etliche der ursprünglich 

 hochpreisigen Biologika verloren im Verlauf der Studie ihren 

 Patentschutz und standen seitdem als kostengünstigere 

 Biosimilars zur Verfügung, sodass ein bedeutsames 

 Verordnungshemmnis entfallen ist. Fragestellung In der 

 vorliegenden Studie wurde untersucht, ob die Verfügbarkeit 

 von Biosimilars mit einer Verbesserung der Versorgung von ERE 

 einhergeht. Zugleich wurde die subjektive Akzeptanz von 

 Biosimilars bei Ärzten und Patienten untersucht und mit 

 standardisierten Scores abgeglichen. Material und Methoden Als 

 Datengrundlage dienten pseudonymisierte Abrechnungsdaten der 

 Kassenärztlichen Vereinigung Bayerns von 2014 bis 2019 sowie 

 eine Paper-Pencil-Befragung von Patienten und Rheumatologen. 

 Ergebnisse Im Beobachtungszeitraum stieg der Anteil an 

 diagnostizierten Patienten, die eine Arzneimitteltherapie 

 erhielten, von 38,5 % auf 43,2 % an. Deren Versorgung 

 veränderte sich auch in Bezug auf die verordneten 

 Wirkstoffe. Die konventionelle medikamentöse Therapie war 

 insgesamt rückläufig. Insbesondere die Verordnung von 

 Glukokortikoiden sank von 39,3 % in 2014 auf 34,3 % in 2019. 

 Zugleich stieg der Anteil zielgerichteter Behandlungen von 12,3 

 % auf 20,4 %. Die mediane Dauer der Basistherapie vor 

 erstmaligem bDMARD-Einsatz verkürzte sich von 3,15 Jahren in 

 2014 auf 2,17 Jahre in 2019. Diskussion Über den 

 Beobachtungszeitraum, in den auch der Markteintritt von 3 

 Biosimilars fällt, verbesserte sich die Versorgung von 

 Patienten mit ERE quantitativ wie qualitativ. Der 

 Versorgungsanteil von Biosimilars nahm parallel zu der 

 aufgezeigten Entwicklung zu. Bei insgesamt hoher Akzeptanz von 

 Biosimilars verweist die Einschätzung des 

 Krankheitsverlaufes von Ärzten und Patienten auf einen 

 leichten, subjektiv wahrgenommenen Vorteil der Therapie mit 

 Originalen im Vergleich zur Biosimilar-Therapie, der sich bei 

 Anwendung standardisierter Scores jedoch nicht bestätigt. 

 Eine mögliche Erklärung hierfür könnte ein 

 Nocebo-Effekt sein, der durch geeignete Kommunikationsstrategien 

 minimiert werden könnte.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Pfeil2022-md,

title = {Further training in rheumatology-Current status 2022},

author = { Alexander Pfeil and Florian Schuch and Martin Fleck},

year  = {2022},

date = {2022-08-01},

journal = {Z. Rheumatol.},

volume = {81},

number = {6},

pages = {482--486},

publisher = {Springer Science and Business Media LLC},

abstract = {For the continued existence of the specialty of internal 

 medicine and rheumatology and the assurance of a qualitative 

 patient care, attractive further education for motivated 

 resident physicians is of central importance. Continuing 

 training in rheumatology takes place primarily in the inpatient 

 setting, although reliable figures on outpatient and inpatient 

 further education positions are not yet available. Further 

 training in rheumatology is predefined by the model further 

 training regulations (Musterweiterbildungsverordnung; MWBO) 

 2018, which have now been implemented by most state medical 

 associations, in some cases with state-specific changes. Based 

 on the MWBO of 2018, a model curriculum was developed by the 

 German Society of Rheumatology (DGRh) for further training in 

 the specialty of internal medicine and rheumatology. This model 

 curriculum is intended to provide orientation for trainees and 

 trainers as well as to facilitate structured rheumatology 

 training in inpatient and outpatient settings.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Simon2022-wz,

title = {Impact of cytokine inhibitor therapy on the prevalence,  seroconversion rate, and longevity of the humoral immune  response against SARS-CoV-2 in an unvaccinated cohort},

author = { David Simon and Koray Tascilar and Arnd Kleyer and Filippo Fagni and Gerhard Krönke and Christine Meder and Peter Dietrich and Till Orlemann and Thorsten Kliem and Johanna Mößner and Anna-Maria Liphardt and Verena Schönau and Daniela Bohr and Louis Schuster and Fabian Hartmann and Moritz Leppkes and Andreas Ramming and Milena Pachowsky and Florian Schuch and Monika Ronneberger and Stefan Kleinert and Axel J Hueber and Karin Manger and Bernhard Manger and Raja Atreya and Carola Berking and Michael Sticherling and Markus F Neurath and Georg Schett},

url = {https://pubmed.ncbi.nlm.nih.gov/34951137/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011429/},

year  = {2022},

date = {2022-05-01},

urldate = {2022-05-01},

journal = {Arthritis Rheumatol.},

volume = {74},

number = {5},

pages = {783--790},

publisher = {Wiley},

abstract = {ÖBJECTIVE: To investigate the impact of biologic 

 disease-modifying antirheumatic drug (bDMARD) treatment on the 

 prevalence, seroconversion rate, and longevity of the humoral 

 immune response against SARS-CoV-2 in patients with 

 immune-mediated inflammatory diseases (IMIDs). METHODS: 

 Anti-SARS-CoV-2 IgG antibodies were measured in a prospective 

 cohort of health care professional controls and non-health care 

 controls and IMID patients receiving no treatment or receiving 

 treatment with conventional or biologic DMARDs during the first 

 and second COVID-19 waves. Regression models adjusting for age, 

 sex, sampling time, and exposure risk behavior were used to 

 calculate relative risks (RRs) of seropositivity. Seroconversion 

 rates were assessed in participants with polymerase chain 

 reaction (PCR)-positive SARS-CoV-2 infection. Antibody response 

 longevity was evaluated by reassessing participants who tested 

 positive during the first wave. RESULTS: In this study, 4,508 

 participants (2,869 IMID patients and 1,639 controls) were 

 analyzed. The unadjusted RR (0.44 [95% confidence interval 

 (95% CI) 0.31-0.62]) and adjusted RR (0.50 [95% CI 0.34-0.73]) 

 for SARS-CoV-2 IgG antibodies were significantly lower in IMID 

 patients treated with bDMARDs compared to non-health care 

 controls (P < 0.001), primarily driven by treatment with tumor 

 necrosis factor inhibitors, interleukin-17 (IL-17) inhibitors, 

 and IL-23 inhibitors. Adjusted RRs for untreated IMID patients 

 (1.12 [95% CI 0.75-1.67]) and IMID patients receiving 

 conventional synthetic DMARDs (0.70 [95% CI 0.45-1.08]) were 

 not significantly different from non-health care controls. Lack 

 of seroconversion in PCR-positive participants was more common 

 among bDMARD-treated patients (38.7%) than in non-health care 

 controls (16%). Overall, 44% of positive participants lost 

 SARS-CoV-2 antibodies by follow-up, with higher rates in IMID 

 patients treated with bDMARDs (RR 2.86 [95% CI 1.43-5.74]). 

 CONCLUSION: IMID patients treated with bDMARDs have a lower 

 prevalence of SARS-CoV-2 antibodies, seroconvert less frequently 

 after SARS-CoV-2 infection, and may exhibit a reduced longevity 

 of their humoral immune response."},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Simon2022-nf,

title = {Humoral and cellular immune responses to SARS-CoV-2 infection 

 and vaccination in autoimmune disease patients with B cell 

 depletion},

author = { David Simon and Koray Tascilar and Katja Schmidt and Bernhard Manger and Leonie Weckwerth and Maria Sokolova and Laura Bucci and Filippo Fagni and Karin Manger and Florian Schuch and Monika Ronneberger and Axel Hueber and Ulrike Steffen and Dirk Mielenz and Martin Herrmann and Thomas Harrer and Arnd Kleyer and Gerhard Krönke and Georg Schett},

year  = {2022},

date = {2022-01-01},

journal = {Ärthritis Rheumatol."},

volume = {74},

number = {1},

pages = {33--37},

publisher = {Wiley},

abstract = {ÖBJECTIVE: B cell depletion is an established therapeutic 

 principle in a wide range of autoimmune diseases. However, B 

 cells are also critical for inducing protective immunity after 

 infection and vaccination. We undertook this study to assess 

 humoral and cellular immune responses after infection with or 

 vaccination against SARS-CoV-2 in patients with B cell depletion 

 and controls who are B cell-competent. METHODS: Antibody 

 responses (tested using enzyme-linked immunosorbent assay) and T 

 cell responses (tested using interferon-$gamma$ enzyme-linked 

 immunospot assay) against the SARS-CoV-2 spike S1 and 

 nucleocapsid proteins were assessed in a limited number of previously infected (n = 6) and vaccinated (n = 8) autoimmune 

 disease patients with B cell depletion, as well as previously infected (n = 30) and vaccinated (n = 30) healthy controls. 

 RESULTS: As expected, B cell and T cell responses to the 

 nucleocapsid protein were observed only after infection, while 

 respective responses to SARS-CoV-2 spike S1 were found after 

 both infection and vaccination. A SARS-CoV-2 antibody response 

 was observed in all vaccinated controls (30 of 30 [100%]) but 

 in none of the vaccinated patients with B cell depletion (0 of 

 8). In contrast, after SARS-CoV-2 infection, both the patients 

 with B cell depletion (spike S1, 5 of 6 [83%]; nucleocapsid, 3 

 of 6 [50%]) and healthy controls (spike S1, 28 of 30 [93%]; 

 nucleocapsid, 28 of 30 [93%]) developed antibodies. T cell 

 responses against the spike S1 and nucleocapsid proteins were 

 found in both infected and vaccinated patients with B cell 

 depletion and in the controls. CONCLUSION: These data show that 

 B cell depletion completely blocks humoral but not T cell 

 SARS-CoV-2 vaccination response. Furthermore, limited humoral 

 immune responses are found after SARS-CoV-2 infection in 

 patients with B cell depletion."},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Pfeil2021-hh,

title = {Model curriculum of the German society for Rheumatology for 

 advanced training in the discipline internal medicine and 

 rheumatology. English version},

author = { Alexander Pfeil and Martin Krusche and Diana Vossen and Michael N Berliner and Gernot Keyßer and Andreas Krause and Hanns-Martin Lorenz and Bernhard Manger and Florian Schuch and Christof Specker and Jürgen Wollenhaupt and Xenofon Baraliakos and Martin Fleck and Fabian Proft},

year  = {2021},

date = {2021-12-01},

journal = {Z. Rheumatol.},

volume = {80},

number = {Suppl 2},

pages = {64--67},

publisher = {Springer Science and Business Media LLC},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Schuch2021-tw,

title = {Rheumatology in practice},

author = { Florian Schuch and Peer Aries},

year  = {2021},

date = {2021-11-01},

journal = {Z. Rheumatol.},

volume = {80},

number = {9},

pages = {793--794},

publisher = {Springer Science and Business Media LLC},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Edelmann2021-cs,

title = {Rheumatology in private practice: yesterday-today-tomorrow},

author = { Edmund Edelmann and Florian Schuch},

year  = {2021},

date = {2021-11-01},

journal = {Z. Rheumatol.},

volume = {80},

number = {9},

pages = {801--818},

publisher = {Springer Science and Business Media LLC},

abstract = {Rheumatologic practices were still rare in the early 1990s and 

 rheumatologic treatment took place mainly in the rheumatology 

 clinics and university rheumatology clinics. In the following 

 decades, the number of the rheumatologists in private practices 

 increased and in the year 2004 about two thirds of the 

 outpatient care were already carried out in private practices. 

 In 2020 a total of 597 rheumatologists out of 1106 nationwide 

 worked in private practices, including 203 who were employed. 

 Since 2008, the number of rheumatologists in medical care 

 centers increased more than the number of rheumatologists in 

 private practice. In 2020 only 75% of panel rheumatologists in 

 private practice were in full-time employment. This development 

 to an altered work mentality of the incoming generation and an 

 age structure in which approximately 30% of panel 

 rheumatologists are older than 60 years, threatens a further 

 deterioration of the anyway insufficient outpatient care. In 

 contrast, there are developments that strengthen the outpatient 

 care especially in practices, such as the outpatient specialist 

 medical care and quality-oriented selective contracts as well as 

 rheumatological and immunological laboratory diagnostics. These 

 cornerstones give rheumatology a special position in the panel 

 medical care within the group of specialties in internal 

 medicine and an attractive economic basis. In addition to the 

 medically and scientifically interesting discipline, this could 

 be a further incentive for young trainees to choose rheumatology 

 as a specialty and working in a private practice.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Schuch2021-hd,

title = {Corona pandemic in the practice : A flashback and reflection 

 from the rheumatological practice},

author = { Florian Schuch},

year  = {2021},

date = {2021-11-01},

journal = {Z. Rheumatol.},

volume = {80},

number = {9},

pages = {795--800},

publisher = {Springer Science and Business Media LLC},

abstract = {The corona pandemic changed the lives of people in Germany in 

 2020. Completely new challenges had to be met in outpatient care 

 and of course also in rheumatology practices. The rapid 

 development, the constant changes, the readjustment, the 

 accompaniment of patients and staff team in this global 

 catastrophe are described. The influence on the daily work and 

 the implementation of new scientific knowledge, e.g. the 

 recommendations of the German Society of Rheumatology (DGRh), 

 are reported. Experiences and insights into what can be learned 

 and taken away from crisis situations are outlined. A detailed 

 chronology of the events, taking the special rheumatological 

 features into account, completes this report of experiences.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Pfeil2021-ka,

title = {Mustercurriculum der Deutschen Gesellschaft für 

 Rheumatologie für die Weiterbildung im Fachgebiet Innere 

 Medizin und Rheumatologie},

author = { Alexander Pfeil and Martin Krusche and Diana Vossen and Michael N Berliner and Gernot Keyßer and Andreas Krause and Hanns-Martin Lorenz and Bernhard Manger and Florian Schuch and Christof Specker and Jürgen Wollenhaupt and Xenofon Baraliakos and Martin Fleck and Fabian Proft},

year  = {2021},

date = {2021-09-01},

journal = {Z. Rheumatol.},

volume = {80},

number = {7},

pages = {688--691},

publisher = {Springer Science and Business Media LLC},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Schwarze2021-ul,

title = {Disease-related knowledge acquisition through structured patient 

 information in rheumatoid arthritis (StruPI-RA) : First 

 results of the StruPI-RA study in Germany},

author = { M Schwarze and V Fieguth and F Schuch and P Sandner and E Edelmann and A Händel and M Kettler and A Hanke and M Kück and L Stein and C Stille and M Fellner and V De 

 Angelis and S Touissant and C Specker},

year  = {2021},

date = {2021-05-01},

journal = {Z. Rheumatol.},

volume = {80},

number = {4},

pages = {364--372},

publisher = {Springer Science and Business Media LLC},

abstract = {Zusammenfassung Hintergrund/Ziel Mit der strukturierten 

 Patienteninformation für Rheumatoide Arthritis (StruPi-RA) 

 liegt das erste standardisierte ambulante 

 Patientenschulungsprogramm für Rheumatoide Arthritis (RA) in 

 Deutschland vor. Das Hauptziel der vorliegenden Studie ist die 

 Erfassung der Wirksamkeit von StruPI-RA in Bezug auf den 

 krankheitsspezifischen Wissenserwerb bei Patienten mit 

 früher RA oder nach Therapiewechsel. Methoden Insgesamt wurden 61 Patienten eingeschlossen: n = 32 in die Interventionsgruppe (IG) und n = 29 in die Kontrollgruppe (KG). 

 Die Intervention umfasste ein strukturiertes 

 Patienteninformationsprogramm (StruPi-RA) zu den Themen 

 Diagnostik, Therapie und Leben mit RA, welches drei 

 90-minütige Module beinhaltet. Die KG erhielt nur einen 

 Patientenratgeber der Deutschen Rheumaliga zur Information 

 über die Erkrankung. Primäres Zielkriterium war der 

 krankheitsbezogene Wissenserwerb, der anhand des Patient 

 Knowledge Questionnaire (PKQ) sowie Erweiterungsfragen zu 2 

 Messzeitpunkten, einmal unmittelbar vor und dann nach 

 Durchführung von StruPI-RA, erhoben wurde. Ergebnisse Die 

 Teilnahme an StruPI-RA führte zu einer signifikanten 

 Verbesserung des krankheitsspezifischen Wissens im Gruppen- und 

 Zeitvergleich zur ungeschulten Gruppe im Original-PKQ sowie in 

 der Fragebogenerweiterung. Ein Einfluss der Krankheitsdauer oder 

 des Bildungsstands wurde nicht beobachtet. Allein in der 

 Subskala Therapie zeigte sich ein signifikanter Unterscheid im 

 Gruppen- und Zeitvergleich. Diskussion Die Teilnehmer am 

 StruPI-RA-Programm hatten im Vergleich zu ungeschulten Patienten 

 einen nachweisbaren krankheitsspezifischen Wissenszuwachs. 

 Dadurch kann sich die Arzt-Patienten-Kommunikation verbessern 

 und eine fundierte Entscheidungsfindung hinsichtlich der 

 Therapie befördert werden. Mittelfristig können sich 

 darüber hinaus eine erhöhte Selbstmanagementkompetenz 

 der Patienten und langfristig auch eine Verbesserung der 

 Lebensqualität sowie der Therapieadhärenz ergeben.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Hoeper2021-nl,

title = {Effect of nurse-led care on outcomes in patients with 

 ACPA/RF-positive rheumatoid arthritis with active disease 

 undergoing treat-to-target: a multicentre randomised controlled 

 trial},

author = { Juliana Rachel Hoeper and Jan Zeidler and Sara Eileen Meyer and Georg Gauler and Patricia Steffens-Korbanka and Martin Welcker and Jörg Wendler and Florian Schuch and Ulrich von 

 Hinüber and Andreas Schwarting and Torsten Witte and Dirk Meyer-Olson and Kirsten Hoeper},

year  = {2021},

date = {2021-04-01},

journal = {RMD Open},

volume = {7},

number = {1},

pages = {e001627},

publisher = {BMJ},

abstract = {ÖBJECTIVE: To determine the non-inferiority of nurse-led care 

 (NLC) in patients with anticitrullinated protein antibody 

 (ACPA)-positive and/or rheumatoid factor (RF)-positive 

 rheumatoid arthritis (RA) with active disease who are starting 

 disease-modifying antirheumatic drug therapy, following 

 treat-to-target (T2T) recommendations. METHODS: A multicentre, 

 pragmatic randomised controlled trial was conducted to assess 

 clinical effectiveness, anxiety, depression and patient 

 satisfaction following a non-inferiority design. The 

 participants were 224 adults with ACPA/RF-positive RA who were 

 randomly assigned to either NLC or rheumatologist-led care 

 (RLC). The primary outcome was the Disease Activity Score in 28 

 Joints measured with C reactive protein (DAS28-CRP) assessed at 

 baseline and after 3, 6, 9 and 12 months. A DAS28-CRP difference 

 of 0.6 was set as the non-inferiority margin. Mean differences 

 between the groups were assessed following per-protocol and 

 intention-to-treat strategies. RESULTS: Demographic data and baseline characteristics of patients in the NLC group (n=111) were comparable to those of patients in the RLC group (n=113). 

 The improvement in disease activity (change in DAS28-CRP, 

 primary outcome) over the course of 12 months was significant in 

 both groups (p<0.001). No significant differences were observed between the NLC and RLC groups (p=0.317). Non-inferiority of NLC 

 was shown for the primary outcome and all secondary outcomes. 

 CONCLUSION: This study supported the non-inferiority of NLC in 

 managing T2T and follow-up care of patients with RA with 

 moderate to high disease activity and poor prognostic factors in 

 addition to RLC. TRIAL REGISTRATION NUMBER: DRKS00013055."},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN9958,

title = {Prevalence of Depressive Symptoms in Patients With Psoriatic Arthritis: Have Numbers Changed During the COVID-19 Pandemic?},

author = { M. Englbrecht and P. Bartz-Bazzanella and C. von der Decken and G. Gauler and P. Wurth and P. Aries and K. Karberg and C. Kuhn and F. Schuch and S. Spathling-Mestekemper and W. Vorbruggen and J. Wendler and M. Welcker and S. Kleinert},

url = {https://www.ncbi.nlm.nih.gov/pubmed/34790678 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591045/pdf/fmed-08-748262.pdf},

doi = {10.3389/fmed.2021.748262},

issn = {2296-858X (Print) 

2296-858X (Linking)},

year  = {2021},

date = {2021-01-01},

journal = {Front Med (Lausanne)},

volume = {8},

pages = {748262},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN9809,

title = {A Real-World Rheumatology Registry and Research Consortium: The German RheumaDatenRhePort (RHADAR) Registry},

author = { S. Kleinert and P. Bartz-Bazzanella and C. von der Decken and J. Knitza and T. Witte and S. P. Fekete and M. Konitzny and A. Zink and G. Gauler and P. Wurth and P. Aries and K. Karberg and C. Kuhn and F. Schuch and S. Spathling-Mestekemper and W. Vorbruggen and M. Englbrecht and M. Welcker and Rhadar Group},

url = {https://www.ncbi.nlm.nih.gov/pubmed/34014170},

doi = {10.2196/28164},

issn = {1438-8871 (Electronic) 

1438-8871 (Linking)},

year  = {2021},

date = {2021-01-01},

journal = {J Med Internet Res},

volume = {23},

number = {5},

pages = {e28164},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN9667,

title = {Cognitive Impairment in axial spondyloarthritis? [abstract]},

author = { S. Kleinert and P. Rapp and F. Schuch and M. Ronneberger and J. Wendler and P. Sternad and F. Popp and P. Bartz-Bazzanella and C. B. Von der Decken and K. Karberg and G. Gauler and P. Wurth and S. Spaethling-Mestekemper and C. Kuhn and M. Englbrecht and W. Vorbrüggen and G. Adler and M. Welcker},

url = {http://ard.bmj.com/content/80/Suppl_1/1274.abstract 

https://ard.bmj.com/content/annrheumdis/80/Suppl_1/1274.full.pdf},

doi = {10.1136/annrheumdis-2021-eular.1353},

year  = {2021},

date = {2021-01-01},

journal = {Annals of the Rheumatic Diseases},

volume = {80},

number = {Suppl 1},

pages = {1274},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN9669,

title = {SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases},

author = { D. Simon and K. Tascilar and F. Fagni and G. Kronke and A. Kleyer and C. Meder and R. Atreya and M. Leppkes and A. E. Kremer and A. Ramming and M. L. Pachowsky and F. Schuch and M. Ronneberger and S. Kleinert and A. J. Hueber and K. Manger and B. Manger and C. Berking and M. Sticherling and M. F. Neurath and G. Schett},

url = {https://www.ncbi.nlm.nih.gov/pubmed/33958324},

doi = {10.1136/annrheumdis-2021-220461},

issn = {1468-2060 (Electronic) 

0003-4967 (Linking)},

year  = {2021},

date = {2021-01-01},

journal = {Ann Rheum Dis},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Krause2020-es,

title = {Delegation ärztlicher Leistungen in der Rheumatologie},

author = { A Krause and K Krüger and J Braun and G Gauler and K Hoeper and F Schuch and A J Voormann},

year  = {2020},

date = {2020-10-01},

journal = {Z. Rheumatol.},

volume = {79},

number = {Suppl 2},

pages = {47--48},

publisher = {Springer Science and Business Media LLC},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Schuch2020-jq,

title = {Die Weiterentwicklung des Curriculums Rheumatologische 

 Fachassistenz DGRh-BDRh -- Medizinische Fachangestellte 

 für Rheumatologie},

author = { F Schuch},

year  = {2020},

date = {2020-10-01},

journal = {Z. Rheumatol.},

volume = {79},

number = {Suppl 2},

pages = {45--46},

publisher = {Springer Science and Business Media LLC},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Fiehn2020-bw,

title = {Aktueller Stand, Ziele und Qualitätsstandards der ambulanten  Versorgung in der Rheumatologie: Positionspapier des  Berufsverbandes der deutschen Rheumatologen (BDRh)},

author = { C Fiehn and X Baraliakos and E Edelmann and S Froschauer and E Feist and K Karberg and J M Ruehlmann and F Schuch and M Welcker and S Zinke},

year  = {2020},

date = {2020-10-01},

urldate = {2020-10-01},

journal = {Z. Rheumatol.},

volume = {79},

number = {8},

pages = {770--779},

publisher = {Springer Science and Business Media LLC},

abstract = {Even in the era of modern guidelines, the treatment of rheumatic 

 diseases is only as good as the framework of rheumatological 

 care within which the treatment is carried out. The access to 

 high-quality medical treatment for all patients is therefore 

 essentially decisive for the prognosis of the patients. This 

 article describes the current state of outpatient treatment in 

 rheumatology and demonstrates which quality projects, such as 

 treatment contracts, outpatient specialized medical treatment 

 (ASV), digitalization and training as specialized 

 rheumatological assistant (RFA), have been created in order to 

 ensure the treatment of our patients. Furthermore, standards are 

 defined that can guarantee a contemporary and guideline-conform 

 treatment in outpatient rheumatological units. As an example it 

 is an affirmation of the Professional Association of German 

 Rheumatologists (BDRh) for ensuring optimal care for all 

 rheumatology patients through early or emergency rheumatology 

 clinics, treat to target, appropriate delegation of medical 

 duties and diversification of treatment, thus an assurance of 

 the quality and comprehensive treatment in rheumatology. The 

 important topic of safeguarding the next generation of 

 rheumatologists, which is indispensable for this, is also 

 discussed.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Krause2020-wu,

title = {Delegation ärztlicher Leistungen in der Rheumatologie},

author = { A Krause and F Schuch and J Braun and G Gauler and K Hoeper and K Krüger and M Wallhäuser and A J Voormann},

year  = {2020},

date = {2020-03-01},

journal = {Z. Rheumatol.},

volume = {79},

number = {2},

pages = {123--131},

publisher = {Springer Science and Business Media LLC},

abstract = {Modern rheumatology enables better and earlier diagnosis and 

 therapy of inflammatory rheumatic system diseases. At the same 

 time, the requirements for the care of rheumatologic patients 

 have risen considerably for non-medical assistant professions 

 and specialists for nursing professions. Since 2006 there has 

 been established an education curriculum ``Rheumatological 

 Specialist Assistant DGRh-BDRh'' (RFA) with the training to 

 become a ``Rheumatological Specialist Assistant (DGRh-BDRh)''. 

 In Europe and in parallel in Germany, assistant professions are 

 increasingly involved in the early detection and care of 

 patients with rheumatic diseases and entrusted with tasks.In 

 this work, the overarching principles for delegation of medical 

 tasks to RFA and recommendations for the delegation are 

 published by the Commission for Delegation of the German Society 

 for Rheumatology (DGRh). These recommendations are based on the 

 requirements of the German Medical Association and have been 

 legally evaluated. With the extension of the training of the RFA 

 board certification is aimed for ``MFA for Rheumatology''. These 

 recommendations enable more transparency and security for 

 delegating doctors and the delegated RFA's.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN9673,

title = {Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion},

author = { D. Simon and K. Tascilar and G. Kronke and A. Kleyer and M. M. Zaiss and F. Heppt and C. Meder and R. Atreya and E. Klenske and P. Dietrich and A. Abdullah and T. Kliem and G. Corte and H. Morf and M. Leppkes and A. E. Kremer and A. Ramming and M. Pachowsky and F. Schuch and M. Ronneberger and S. Kleinert and C. Maier and A. J. Hueber and K. Manger and B. Manger and C. Berking and M. Tenbusch and K. Uberla and M. Sticherling and M. F. Neurath and G. Schett},

url = {https://www.ncbi.nlm.nih.gov/pubmed/32709909},

doi = {10.1038/s41467-020-17703-6},

issn = {2041-1723 (Electronic) 

2041-1723 (Linking)},

year  = {2020},

date = {2020-01-01},

journal = {Nat Commun},

volume = {11},

number = {1},

pages = {3774},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN9624,

title = {Chronic Kidney Disease Is Underestimated in Patients with Rheumatoid Arthritis – Real World Data Gathered from a Network of Rheumatologists [abstract]},

author = { Kleinert S and Bartz-Bazzanella P and von der Decken C and Karberg K and Schuch F and Gauler G and Wurth P and Spaethling-Mestekemper S and Kuhn C and Englbrecht M and Vorbrueggen W and Welcker M.},

year  = {2020},

date = {2020-01-01},

journal = {Arthritis Rheumatol.},

volume = {72 (suppl 10).},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN9615,

title = {How many of your patients have depressive symptoms? How to assess during routine clinical practice?},

author = { Stefan Kleinert and Florian Schuch and Praxedis Rapp and Monika Ronneberger and Joerg Wendler and Matthias Englbrecht},

year  = {2019},

date = {2019-01-01},

journal = {Ann Rheum Dis},

volume = {78},

pages = {A638},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN9625,

title = {Dealing with comorbidities in rheumatoid arthritis with medical assistants. The patients’ opinion on assessment and education by medical assistants during routine clinical practice [abstract]},

author = { Stefan Kleinert and Praxedis Rapp and Monika Ronneberger and Joerg Wendler and Florian Schuch},

year  = {2019},

date = {2019-01-01},

journal = {Ann Rheum Dis},

volume = {78, supplement 2},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Figueiredo2017-hw,

title = {Antimodified protein antibody response pattern influences the  risk for disease relapse in patients with rheumatoid arthritis  tapering disease modifying antirheumatic drugs},

author = { Camille P Figueiredo and Holger Bang and Jayme Fogagnolo Cobra and Matthias Englbrecht and Axel J Hueber and Judith Haschka and Bernhard Manger and Arnd Kleyer and Michaela Reiser and Stephanie Finzel and Hans-Peter Tony and Stefan Kleinert and Joerg Wendler and Florian Schuch and Monika Ronneberger and Martin Feuchtenberger and Martin Fleck and Karin Manger and Wolfgang Ochs and Matthias Schmitt-Haendle and Hanns-Martin Lorenz and Hubert Nuesslein and Rieke Alten and Joerg Henes and Klaus Krueger and Jürgen Rech and Georg Schett},

year  = {2017},

date = {2017-02-01},

urldate = {2017-02-01},

journal = {Ann. Rheum. Dis.},

volume = {76},

number = {2},

pages = {399--407},

abstract = {ÖBJECTIVE: To perform a detailed analysis of the autoantibody 

 response against post-translationally modified proteins in 

 patients with rheumatoid arthritis (RA) in sustained remission 

 and to explore whether its composition influences the risk for 

 disease relapse when tapering disease modifying antirheumatic 

 drug (DMARD) therapy. METHODS: Immune responses against 10 

 citrullinated, homocitrullinated/carbamylated and acetylated 

 peptides, as well as unmodified vimentin (control) and cyclic 

 citrullinated peptide 2 (CCP2) were tested in baseline serum 

 samples from 94 patients of the RETRO study. Patients were 

 classified according to the number of autoantibody reactivities 

 (0-1/10, 2-5/10 and >5/10) or specificity groups (citrullination, 

 carbamylation and acetylation; 0-3) and tested for their risk to 

 develop relapses after DMARD tapering. Demographic and 

 disease-specific parameters were included in multivariate 

 logistic regression analysis for defining the role of 

 autoantibodies in predicting relapse. RESULTS: Patients varied in 

 their antimodified protein antibody response with the extremes 

 from recognition of no (0/10) to all antigens (10/10). Antibodies 

 against citrullinated vimentin (51%), acetylated ornithine 

 (46%) and acetylated lysine (37%) were the most frequently observed subspecificities. Relapse risk significantly (p=0.011) 

 increased from 18% (0-1/10 reactivities) to 34% (2-5/10) and 

 55% (>5/10). With respect to specificity groups (0-3), relapse risk significantly (p=0.021) increased from 18% (no reactivity) 

 to 28%, 36% and finally to 52% with one, two or three antibody 

 specificity groups, respectively. CONCLUSIONS: The data suggest 

 that the pattern of antimodified protein antibody response 

 determines the risk of disease relapse in patients with RA 

 tapering DMARD therapy. TRIAL REGISTRATION NUMBER: 

 2009-015740-42; Results."},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN8609,

title = {Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs},

author = { C. P. Figueiredo and H. Bang and J. F. Cobra and M. Englbrecht and A. J. Hueber and J. Haschka and B. Manger and A. Kleyer and M. Reiser and S. Finzel and H. P. Tony and S. Kleinert and J. Wendler and F. Schuch and M. Ronneberger and M. Feuchtenberger and M. Fleck and K. Manger and W. Ochs and M. Schmitt-Haendle and H. M. Lorenz and H. Nuesslein and R. Alten and J. Henes and K. Krueger and J. Rech and G. Schett},

url = {https://www.ncbi.nlm.nih.gov/pubmed/27323772 

http://ard.bmj.com/content/annrheumdis/76/2/399.full.pdf},

doi = {10.1136/annrheumdis-2016-209297},

issn = {1468-2060 (Electronic) 

0003-4967 (Linking)},

year  = {2017},

date = {2017-01-01},

journal = {Ann Rheum Dis},

volume = {76},

number = {2},

pages = {399-407},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN7751,

title = {Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study},

author = { J. Haschka and M. Englbrecht and A. J. Hueber and B. Manger and A. Kleyer and M. Reiser and S. Finzel and H. P. Tony and S. Kleinert and M. Feuchtenberger and M. Fleck and K. Manger and W. Ochs and M. Schmitt-Haendle and J. Wendler and F. Schuch and M. Ronneberger and H. M. Lorenz and H. Nuesslein and R. Alten and W. Demary and J. Henes and G. Schett and J. Rech},

url = {http://www.ncbi.nlm.nih.gov/pubmed/25660991},

doi = {10.1136/annrheumdis-2014-206439},

issn = {1468-2060 (Electronic) 

0003-4967 (Linking)},

year  = {2016},

date = {2016-01-01},

journal = {Ann Rheum Dis},

volume = {75},

number = {1},

pages = {45-51},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN8206,

title = {Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment},

author = { J. Rech and A. J. Hueber and S. Finzel and M. Englbrecht and J. Haschka and B. Manger and A. Kleyer and M. Reiser and J. F. Cobra and C. Figueiredo and H. P. Tony and S. Kleinert and J. Wendler and F. Schuch and M. Ronneberger and M. Feuchtenberger and M. Fleck and K. Manger and W. Ochs and M. Schmitt-Haendle and H. M. Lorenz and H. Nuesslein and R. Alten and J. Henes and K. Krueger and G. Schett},

url = {https://www.ncbi.nlm.nih.gov/pubmed/26483255 

http://ard.bmj.com/content/annrheumdis/75/9/1637.full.pdf},

doi = {10.1136/annrheumdis-2015-207900},

issn = {1468-2060 (Electronic) 

0003-4967 (Linking)},

year  = {2016},

date = {2016-01-01},

journal = {Ann Rheum Dis},

volume = {75},

number = {9},

pages = {1637-44},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN9102,

title = {Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study},

author = { J. Haschka and M. Englbrecht and A. J. Hueber and B. Manger and A. Kleyer and M. Reiser and S. Finzel and H. P. Tony and S. Kleinert and M. Feuchtenberger and M. Fleck and K. Manger and W. Ochs and M. Schmitt-Haendle and J. Wendler and F. Schuch and M. Ronneberger and H. M. Lorenz and H. Nuesslein and R. Alten and W. Demary and J. Henes and G. Schett and J. Rech},

url = {https://ard.bmj.com/content/annrheumdis/75/1/45.full.pdf},

doi = {10.1136/annrheumdis-2014-206439},

issn = {0003-4967},

year  = {2015},

date = {2015-01-01},

journal = {Ann Rheum Dis},

keywords = {},

pubstate = {published},

tppubtype = {article}

}